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The ability of five purified amphibian antimicrobial peptides (dermaseptin-1, temporin A, magainin I, and II, PGLa), crude peptide
fractions isolated from the skin of Rana pipiens and R. catesbeiana, and four antimicrobial peptides (AMPs) from hybrid striped bass
(piscidin-1N, -1H, -2, and -3) were examined for their ability to reduce the infectivity of channel catfish virus (CCV) and frog virus 3 (FV3).
All compounds, with the exception of magainin I, markedly reduced the infectivity of CCV. In contrast to CCV, FV3 was 2- to 4-fold less
sensitive to these agents. Similar to an earlier study employing two other amphibian peptides, the agents used here acted rapidly and over a
wide, physiologically relevant, temperature range to reduce virus infectivity. These results extend our previous findings and strongly suggest
that various amphibian and piscine AMPs may play important roles in protecting fish and amphibians from pathogenic viruses.
D 2004 Elsevier Inc. All rights reserved.Keywords: Antimicrobial peptides; Channel catfish virus; Herpesvirus; Frog virus 3; Iridovirus; Ectothermic organisms; Amphibian decline; Temporin;
Dermaseptin; Magainin; Piscidins; RanatuerinIntroduction
Antimicrobial peptides (AMPs) are low-molecular-
weight molecules (approximately 1–5 kDa) possessing
potent inhibitory activity against a wide range of bacteria,
fungi, and viruses. To date, more than 750 AMPs have been
isolated from a phylogenetically diverse collection of organ-
isms including mammals, fish, amphibians, and insects
(Boman, 1995; Brogden et al., 2003; Hancock and Chapple,
1999; Lehrer et al., 1993; Nicolas and Mor, 1995; Tossi;
Zasloff, 2002). The majority of AMPs are cationic, amphi-
pathic molecules, which can be loosely grouped into cate-
gories that reflect their primary and secondary structure
(Zasloff, 2002): alpha helical peptides (e.g., cecropins);
proline- (e.g., bactenecins), glycine- (e.g., attacins), or0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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one (e.g., ranatuerins) or more (e.g., protegrins and defen-
sins) disulphide bonds. In contrast, there are smaller groups
of AMPs composed of anionic peptides, aromatic dipep-
tides, processed forms of oxygen-binding proteins, and
peptides derived from neuropeptide precursors (Brogden et
al., 2003; Salzet, 2002; Stefano et al., 1998). For example,
enkelytin, a 31-amino-acid peptide containing seven gluta-
mic acid residues, is generated by cleavage of proenkepha-
lin-A (Goumon et al., 1998), and three ovine heptapeptides
were identified that contain six to seven aspartic acid
residues (Brogden et al., 1996). Among the larger class of
cationic AMPs, the principal structural feature common to
all is their ability to adopt an amphipathic configuration in
which clusters of hydrophobic and cationic amino acids are
spatially organized such that the molecule possesses discrete
hydrophobic and hydrophilic faces (Oren and Shai, 1998). It
is thought that AMPs exert their antimicrobial effects by
interacting with negatively charged phospholipid head-
groups present on the outermost leaflet of bacterial mem-
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action leads to lipid displacement, changes in membrane
structure, and, in some cases, entry of the peptide into the
interior of the bacterial cell (Oren and Shai, 1998; Zasloff,
2002; Zhao et al., 2002). Although the precise mechanism is
unclear, killing is thought to involve one or more of the
following: fatal membrane depolarization, membrane pore
formation leading to loss of intracellular contents, induction
of hydrolases, disturbance of membrane function, and
specific damage to critical intracellular targets. In contrast
to the deleterious effect of AMPs on bacterial membranes,
eukaryotic cells are relatively resistant to destabilization due
to the presence of cholesterol within the plasma membrane
and by the absence of negatively charged phospholipids on
the outermost leaflet of the plasma membrane (Lichtenstein,
1991; Oren and Shai, 1998).
Although it has been known for some time that AMPs
show broad antibacterial and antifungal activity in vitro,
recent in vivo studies support a role for AMPs in protection
from overt disease. For example, mice expressing human
defensin 5 survived infection with Salmonella typhimurium,
whereas normal mice lacking this AMP succumbed to
infection within 2 days (Salzman et al., 2003). In another
study, mice with a disruption within the gene encoding the
AMP cathelicidin developed persistent infections following
exposure to h-hemolytic Group A Streptococcus, whereas
wild-type mice were resistant to infection (Nizet et al., 2001).
In addition to playing a direct role in pathogen destruction,
AMPs are also thought to enhance immune defenses by
modulating innate and acquired immune responses (Salzet,
2002; Stefano et al., 1998; Yang et al., 2002). Thus, the dual
role of AMPs as effectors of innate immunity and inducers of
both innate and adaptive responses may place AMPs at the
center of immune defense strategies.
Although most studies to date have focused on protection
against bacterial and fungal pathogens, AMPs have also been
shown to be effective against viral pathogens (Daher et al.,
1986; Lehrer et al., 1985; Yasin et al., 2000; Zhang et al.,
2002). The defensin human neutrophil peptide -1 (HNP-1)
inactivated enveloped viruses such as herpes simplex virus
types 1 and 2 (HSV-1, -2), vesicular stomatits virus (VSV),
and influenza A virus, but had little to no effect against
another herpesvirus, cytomegalovirus (CMV), as well as two
non-enveloped viruses, ECHO virus 11 and reovirus type 3
(Daher et al., 1986). In a similar manner, two additional
defensins, rabbit lung macrophage peptides MCP-1 and
MCP-2, demonstrated in vitro neutralizing activity against
HSV-2, VSV, and influenza A, but showed little activity
against CMV, reovirus type 3, or ECHO virus 11 (Lehrer et
al., 1985). Interestingly, several similar peptides were mark-
edly less effective against HSV-1 indicating that small differ-
ences in the primary structure of the AMPmay produce major
differences in antiviral activity (Lehrer et al., 1985). Recently
human a-defensins -1, -2, and -3 were suggested to possess
anti-HIV-1 activity and to account for some, but not all, of the
non-lytic, anti-HIV activity of CD8 T cells (Chang et al.,2003; Zhang et al., 2002). These results indicate that although
the degree of viral inactivation varies markedly with the type
of AMP and the species of virus, AMPs likely play an
important role in antiviral immunity.
Although AMPs were first isolated from amphibian skin
over 30 years ago (Csordas and Michl, 1970), it was not until
recently that the effects of amphibian AMPs have been
measured against amphibian pathogens. Recent studies
showed that a panel of amphibian AMPs (magainin -I and -
II, CPF, PGLa, dermaseptin, and ranalexin) inhibited the
growth of the fungi Batrachochytrium dendrobatidis and
Basidiobolus ranarum, although having no effect on the
bacterium Aeromonas hydrophilia (Rollins-Smith et al.,
2002b). Other peptides from North American ranid frogs
and the European frog Rana temporaria were also shown to
inhibit the growth of B. dendrobatidis (Rollins-Smith et al.,
2002a, 2002c, 2003). These results are ecologically signifi-
cant because B. dendrobatidis is the fungal agent recently
linked to the global decline of amphibians (Daszak et al.,
1999). In addition to amphibians, AMPs have also been
detected in several species of fish (Cole et al., 1997; Fer-
nandes et al., 2004; Noga and Silphaduang, 2003; Oren and
Shai, 1996; Silphaduang and Noga, 2001; Smith et al., 2000),
for example, winter flounder Pleuronectes americanus (pleu-
rocidin), rainbow troutOncorhynchus mykiss (an unnamed 3-
kDa cationic peptide and a 60-residue cleavage product of
histone H1 termed oncorhyncin II), Moses sole Pardachirus
marmoratus (pardaxin), and hybrid striped bass Marone
saxatilisM. chrysops (piscidin). As with amphibian AMPs,
fish AMPs inactivated many mammalian and fish bacterial
pathogens including Escherichia coli, Pseudomonas aerugi-
nosa, Staphlycoccus aureus, A. hydrophilia, A. salmonicida,
and Streptococcus iniae (Cole et al., 1997; Oren and Shai,
1996; Silphaduang and Noga, 2001; Smith et al., 2000).
Given the potential importance of AMPs to antiviral
immunity, we examined the ability of a panel of amphibian
and piscine AMPs to inactivate two viral pathogens of
ectothermic animals, channel catfish virus (CCV, family
Herpesviridae, genus unassigned, Hanson, 2002) and frog
virus 3 (FV3, family Iridoviridae, genus Ranavirus, Chin-
char, 2002). Our results indicate that amphibian and piscine
AMPs inactivate both pathogens, albeit with different effi-
ciencies. Moreover, inactivation is rapid and occurs, in
contrast to mammalian AMPs, over a wide temperature
range. These results suggest that AMP-mediated viral inac-
tivation may play an important part in protection from viral
disease.Results
Antiviral activity of single amphibian peptides
In initial experiments, we examined the ability of seven
AMPs, originally isolated from amphibians, to inactivate
CCV, an enveloped virus that is a major pathogen of
Fig. 2. Effect of magainin II and PGLa on CCV infectivity. CCV was
incubated in the presence of the indicated concentrations of either magainin
II (filled circles) or PGLa (open triangles) for 60 min at 26 jC and the
residual infectivity determined by plaque assay. The data shown here
represent the means from two to five replicative experiments.
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show the effects of varying concentrations of four amphib-
ian AMPs (dermaseptin, temporin A, PGLa, and magainin
II) on CCV infectivity. These results, summarized in Table
2, indicate that dermaseptin ([i]50 = 3 AM) and temporin A
([i]50 = 15 AM) were more effective than PGLa ([i]50 = 100
AM) and magainin II ([i]50 = 48 AM) in reducing the
infectivity of CCV. Surprisingly, magainin I appeared to
have only limited ability to inactivate CCV (data not
shown). Based on these results, we examined the ability
of dermaseptin and temporin A, the two most active com-
pounds, to reduce the infectivity of FV3, a non-enveloped
virus that is the type species of the genus Ranavirus and an
emerging pathogen of frogs (Chinchar, 2002; Daszak et al.,
1999). As shown in Fig. 1, both dermaseptin and temporin
A reduced the infectivity of FV3, although AMP concen-
trations 3- to 4-fold higher than those required for CCV
inactivation were needed. Because AMPs are thought to act
by membrane perturbation, the higher AMP concentrations
required for FV3 inactivation may reflect the fact that CCV
is an enveloped virus, whereas FV3 is non-envelopedFig. 1. Effect of dermaseptin-1 and temporin A on the infectivity of CCV
and FV3. CCV and FV3 were incubated in the presence of the indicated
concentrations of peptides for 60 min at 26 jC and the residual infectivity
was determined by plaque assay. Upper panel: dermaseptin-1 vs. CCV and
FV3; lower panel: temporin A vs. CCV and FV3. A representative
experiment is shown.(Chinchar et al., 2001). Finally, in addition to studies using
purified AMPs, crude peptide preparations from Rana
pipiens and R. catesbeiana were also shown to inactivate
CCV (Fig. 3).
Synergistic effect of AMPs
Next, we determined whether synergy occurred when
virions were incubated in the presence of AMPs from
different structural classes. Increased inactivation was
detected when CCV was treated with a combination of
ranatuerin-2P and magainin II (Fig. 4), dermaseptin and
ranatuerin-2P (data not shown), or dermaseptin and escu-
lentin-2P (data not shown). However, because about the
same level of inactivation was achieved by simply doubling
the concentration of each individual AMP, apparently, theFig. 3. Effect of a crude preparation of amphibian skin peptides on CCV
infectivity. Partially purified peptides prepared from the skin of R.
catesbeiana (open circles) and R. pipiens (filled circles ) were monitored
for their ability to inactivate CCV as described above. A representative
experiment is shown.
Fig. 4. Interaction between various antimicrobial peptides. Effect of
ranatuerin-2P and magainin II, singly and in combination, on the infectivity
of CCV. The concentration of each AMP used is indicated below the bar;
‘‘MIX’’ indicates 5 AM R2P and 50 AM magainin II. Shown is the mean
and standard deviation of two experiments.
Fig. 5. Effect of temperature and time on the inactivation kinetics of various
amphibian antimicrobial peptides. Upper panel: effect of temperature on the
inactivation of CCV; lower panel: effect of increasing incubation time on
inactivation of CCV. Concentrations of peptides were chosen which
reduced CCV infectivity by >90% following a 60-min incubation at 26 jC.
The means of two to four replicative experiments are shown. Sample
standard deviations were generally < 10%.
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than synergistic, effect. These results are in contrast to
previous findings in which combinations of magainin II
and PGLa showed clear evidence of synergy when tested
against B. dendrobatidis (Rollins-Smith et al., 2002b).
Effect of temperature on activity of AMPs
Previously, we showed that two AMPs from amphibians,
ranatuerin-2P (R2P) and esculentin-2P (E2P) rapidly
inhibited CCV at both ‘‘normal’’ environmental temper-
atures (26 jC) and at two lower (4 and 14 jC), but still
physiologically relevant, temperatures (Chinchar et al.,
2001). To determine if representative members of this new
panel of AMPs behaved in a similar fashion, we monitored
the ability of temporin A, dermaseptin, a crude peptide
fraction from R. pipiens, and R2P to inactivate CCV over a
range of temperatures and times. In the first series of
experiments, inactivation was monitored over a range of
physiologically relevant temperatures. As seen in Fig. 5
(upper panel), all four AMPs were about as active at 14 jC
as they were at 26 jC. Moreover, except for temporin A,
they retained considerable activity at 4 jC. In the next study,
inactivation was monitored following incubation for in-
creasing periods of time at 26 jC. Consistent with earlier
results, most infectivity was lost within 10 min (Fig. 5,
bottom panel) indicating that the AMPs acted rapidly to
inactivate infectivity.
Antiviral activity of a novel class of fish AMPs
Lastly, we examined the impact of four piscine AMPs
on CCV infectivity. The four AMPs studied were originally
isolated from hybrid striped bass (M. saxatilis  M.
chrysops) and shown to be effective against a variety of
bacterial pathogens (Silphaduang and Noga, 2001). The
four piscidins are structurally very similar to each other
(Table 1). Two of them, piscidin-1N and piscidin-1H,
differ only in the presence or absence of an amidated C-
terminus, a feature that is found in naturally occurringTable 1
Primary structure of antimicrobial peptidesa
Temporin A FLPLIGRVLSGIL.NH2
Dermaseptin-1ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ
Magainin I GIGKFLHSAGKFGKAFVGEIMKS
Magainin II GIGKFLHSAKKFGKAFVGEIMNS
PGLa GMASKAGAIAGKIAKVALKAL.NH2
Piscidin-1 FFHHIFRGIVHVGKTIHRLVTGb
Piscidin-2 FFHHIFRGIVHVGKTIHKLVTG
Piscidin-3 FIHHIFRGIVHAGRSIGRFLTG
Ranatuerin-2P GLMDTVKNVAKNLAGHMLDKLKCKITGC
Esculentin-2P GFLSIFRGVAKFASKGLGKDLARLGVNLVACKISKQC
a Basic amino acids are shown in bold typeface, and cysteine residues
involved in disulfide bond formation are underlined.
b Because natural piscidins sometimes have an amidated carboxy terminus,
piscidin-1 has been synthesized in both the amide (piscidin-1N) and acid
(piscidin-1H) forms.
Fig. 6. Effect of piscidins on the infectivity of CCV. CCV was incubated in
the presence of the indicated concentrations of piscidin-1H, -1N, -2, or -3 at
26 jC for 60 min and assayed for residual infectivity by plaque assay. The
data depict the means of two to three experiments.
Fig. 7. Effect of temperature and time on the inactivation of CCV by
Piscidin-1, -2, and -3. CCV was incubated in the presence of 25 Ag/ml
Piscidin-1N, -1H, and -2, or 50 Ag/ml Piscidin-3, for 60 min at 4j, 14j, or
26 jC (Upper Panel) or for the indicated period of time at 26 jC (Lower
Panel). Residual infectivity was determined by plaque assay, and the means
of two to three experiments are shown.
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substitution at amino acid position 18 (Silphaduang and
Noga, 2001). Fig. 6 indicates that all four piscidins
possessed marked antiviral activity and Table 2 shows that
they are as active on a molar basis as dermaseptin and
temporin A. In a follow up to these studies, we also
examined the influence of incubation time and temperature
on loss of infectivity. As with the amphibian-derived
peptides, the four piscidins tested acted rapidly and over
a wide temperature range (Fig. 7). Experiments monitoring
the ability of piscidins to inactivate FV3 showed that, as
with the above studies, FV3 inactivation took place, but
that a higher concentration of piscidin was required to
achieve inactivation of FV3 compared to CCV (Table 2).
Effect of AMPs on host cells
Although exhibiting marked antiviral activity, the two
most active AMPs tested did not appear to be cytolytic forTable 2
Antiviral activity of amphibian and piscine AMPs
Peptide [i]50
a
CCV FV3
Dermaseptin-1 3 AM 12 AM
Temporin A 15 AM 58 AM
Magainin II 48 AM ND
PGLa 100 AM NDb
R. catesbeiana peptides 78 Ag/ml ND
R. pipiens peptides 42 Ag/ml ND
Piscidin-1N 4 AM 13 AM
Piscidin-1H 4 AM 13 AM
Piscidin-2 4 AM 13 AM
Piscidin-3 11 AM 16 AM
a [i]50 denotes the concentration of AMP that reduced viral infectivity by
50%. The values shown represent the average of two or more experiments.
b ND denotes ‘‘not determined.’’uninfected cells. As shown by trypan blue staining and
visual inspection of cell cultures, dermaseptin-1 (0.1–11.4
AM) and piscidin-1N (0.25–25 Ag/ml) did not kill CCO
cells following exposure to either compound for as long as
20 h (data not shown). Interestingly, despite the apparent
lack of cytolytic activity, we detected about a 20% decrease
(average of four experiments) in the ability of CCO cells to
metabolize MTT following a 3-h exposure to 25 Ag/ml
piscidin-1N or -2. In contrast, CCO cells exposed to 5.7 AM
dermaseptin-1 showed essentially no decrease in their
ability to metabolize MTT. Collectively, these results sug-
gest that AMPs, at concentrations that reduce viral infec-
tivity by >90%, are not cytolytic for host cells.Discussion
The above results confirm and extend our earlier work
and demonstrate that an expanded panel of amphibian and
piscine AMPs possessed marked antiviral activity. The
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suggests that they are an evolutionary ancient weapon in
the continuing fight against microbial invaders (Stefano et
al., 1998; Zasloff, 2002), and likely play a role in
protecting lower vertebrates from infection. As seen pre-
viously, CCV was more sensitive to inactivation than
FV3, a result which may reflect the enveloped character
of the former (Chinchar et al., 2001). However, although
most FV3 particles lack a conventional viral envelope,
FV3 possesses a lipid membrane located between the
outer capsid coat and the inner DNA core (Chinchar,
2002). Whether the ability of the tested AMPs to reduce
the infectivity of FV3 is due to their capacity to interact
with this essential lipid membrane, or whether it reflects
interaction between AMPs and the protein shell itself is
not known. We favor the former mechanism because non-
enveloped mammalian viruses such as reovirus 3 and
ECHO virus 11 are resistant to AMP-mediated inactiva-
tion (Daher et al., 1986; Lehrer et al., 1985). However,
sensitivity of a given virus to an AMP is not simply
determined by the presence or absence of an envelope
because enveloped viruses demonstrated a 1000-fold dif-
ference in sensitivity to HNP-1 (Daher et al., 1986).
The mechanism by which AMPs reduce virus infec-
tivity remains to be determined. In contrast to the work of
Daher et al. (1986), our previous electron microscopic
study showed that R2P and E2P appeared to destabilize
CCV, whereas treated FV3 remained ostensibly intact
(Chinchar et al., 2001). These results were surprising
because, although one might have expected that AMPs
would destabilize the CCV envelope, one would have
predicted that the resulting viral nucleocapsids would
have remained intact. This did not appear to be the case
as both the envelope and underlying nucleocapsid were
destabilized. Furthermore, because the lipid component of
the viral envelope is derived from the host cell’s plasma
membrane, and because the latter is relatively resistant to
AMP attack, it is unclear why the viral envelope should
be degraded. Perhaps the presence of viral proteins or
externally orientated phosphadtidylserine within the viral
envelope alters its properties and enhances its suscepti-
bility to AMP attack.
As seen earlier, amphibian and piscine AMPs were
active over a greater temperature range than mammalian
AMPs. For example, in assays involving HSV-1 and the
mammalian AMP HNP-1, there were successive 10-fold
drops in activity as the incubation temperature was
progressively lowered from 42 to 37 jC, 37 to 26 jC,
and 26 to 14 jC (Daher et al., 1986). Similar losses in
antiviral activity were also seen with MCP-1 and MCP-2
(Lehrer et al., 1985). In contrast to mammalian AMPs,
ectothermic AMPs showed about as much as activity at
14 jC as they did at 26 jC, and retained considerable
activity at temperatures as low as 4 jC. The wider
temperature range over which amphibian and piscine
AMPs appear to function may reflect the need foramphibian and piscine AMPs to provide protection over
a wider range of environmentally relevant temperatures,
whereas mammalian AMPs are active only within a
narrow physiological temperature range.
Despite increasing evidence for their ability to inactivate
viruses in vitro, a definitive role for AMPs in protecting
amphibians and fish from virus infection has not yet been
established. Moreover, determining the precise role that
various AMPs play in protection from infectious disease
will be challenging. For example, treatments (e.g., mild
electrical stimulation or exposure to adrenergic agents)
designed to release AMPs and generate AMP-deficient
animals may also suppress other aspects of innate and
acquired immunity and make it difficult to determine the
relative contribution of AMPs. However, if, as suggested for
mammals, amphibian and piscine AMPs also play a role in
regulating innate and adaptive immunity (Yang et al., 2002),
then one can envision a scenario in which AMPs act as a
first line of defense and block virus infection by direct
inactivation, or, if that is not successful, control and elim-
inate infection by upregulating additional innate and adap-
tive responses.Methods
Cells and viruses
The propagation of FV3 in fathead minnow (FHM)
cells (ATCC No. CCL 42) and of CCV in channel catfish
ovary (CCO) cells (Bowser and Plumb, 1980) has been
described previously (Chinchar et al., 2001). Virus samples
were prepared in either Dulbecco’s modified Eagle medi-
um (DMEM) containing 4% fetal calf serum (FCS) or in
RSB (10 mM Tris–HCl, pH 7.5, 10 mM NaCl, 1.5 mM
MgCl2).
Antimicrobial peptides
Temporin A was synthesized as previously described
(Wade et al., 2001). With the exception of PGLa, which
was a gift from Magainin Pharmaceuticals (Plymouth Meet-
ing, PA), the other amphibian peptides used in this study
were either synthesized by Sigma/Genosys (ranatuerin-2P)
or purchased from Sigma (St. Louis, MO) (dermaseptin-1,
magainin I, magainin II). Amphibian AMPs were dissolved
in sterile water at concentrations ranging from 114 to 1000
AM, and stored at 80 jC. The piscidins employed in this
study were synthesized using Fmoc chemistry on a Rainin
Symphony synthesizer. Piscidin stock solutions were pre-
pared at 4 mg/ml in 0.01% acetic acid and stored at 80 jC.
Working solutions of all peptides were prepared by dilution
in sterile water and the indicated concentrations tested for
their ability to reduce virus infectivity as described below.
The primary amino acid sequences of the AMPs used in this
study are shown in Table 1.
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Crude peptide fractions were prepared from R. catesbei-
ana and R. pipiens as follows. Individual frogs were injected
bilaterally with 2 nmol/g body weight of [+/]-norepineph-
rine hydrochloride in a volume of 0.1 ml per 10 g frog
weight via the dorsal lymph sac. Immediately following
injection, the frog was placed in 100 ml of collection buffer
(25 mM NaCl, 25 mM sodium acetate, pH 7.0) (Giovannini
et al., 1987), and skin secretions were allowed to accumulate
in the buffer for 15 min. Following release of skin secre-
tions, the frog was removed, and the buffer was acidified by
addition of 1.0 ml of trifluoroacetic acid (TFA). The skin
secretions were partially purified by passage over a C-18
Sep-Pak cartridge (Waters Corporation, Milford, MA) as
previously described (Goraya et al., 1998, 2000). Protein
concentration was determined using the Micro BCA* Assay
(Pierce, Rockford, IL) following manufacturer’s instructions
except that Bradykinin (RPPGFSPFR) (Sigma) was used to
establish a standard curve (Smith et al., 1985).
Assay of residual virus infectivity
The efficacy of individual AMPs in reducing virus
infectivity was determined by plaque assay. Briefly, 10
Al of virus (containing between 106 and 108 PFU/ml) were
mixed with an equal volume of AMP (or sterile water) and
incubated at 26 jC for 1 h. At that time, samples were
diluted with 1 ml of DMEM containing 4% FCS and
stored on ice. Samples were subsequently serially diluted
10-fold and the residual virus titer determined by plaque
assay on either CCO cells (for CCV) or FHM cells (for
FV3). In some cases, residual levels of virus infectivity
were determined by TCID50 assay. Individual inactivation
experiments were performed two or more times. Virus
titers are expressed as ‘‘percentage of control’’ [i.e., (virus
+ peptide/virus + water)  100]. Addition of the AMP to
the virus inoculum did not change the color of the growth
medium in which the virus was prepared, suggesting that
decreases in infectivity were not due to changes in pH.
Moreover, plaque assay confirmed that the dilute acid
present within the piscidin samples did not reduce viral
infectivity (data not shown).
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